AzTrials
AzTrials

Advanced Solid TumorPhase 2RAGNARNCT04083976

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

A Phase 2 study testing Erdafitinib in people with Advanced Solid Tumor, run by Janssen Research & Development, LLC at 179 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). Read more about this study

Who is it for?
Ages 6 years and older
Conditions the study is for
Advanced Solid Tumor
What is being tested?
Erdafitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
316 participants
Where
179 sitesin 15 countries
Study dates
20 Nov 2019to 28 Feb 2026
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Histologic demonstration of an unresectable, locally advanced, or metastatic solid tumor malignancy with an fibroblast growth factor receptor (FGFR) mutation or FGFR gene fusion
  • Measurable disease
  • Participant must have received at least one prior line of systemic therapy in the advanced, unresectable, or metastatic setting; or is a child or adolescent participant with a newly-diagnosed solid tumor and no acceptable standard therapies
  • Documented progression of disease, defined as any progression that requires a change in treatment, prior to full study screening

Who cannot join

  • Has had prior chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 15 days or less than or equal to (<=) 5 half-lives of the agent (whichever is longer) and up to a maximum of 30 days before the first dose of erdafitinib
  • The presence of FGFR gatekeeper and resistance mutations
  • Histologic demonstration of urothelial carcinoma
  • Hematologic malignancy (i.e., myeloid and lymphoid neoplasms
  • For non-small cell lung cancer participants only: pathogenic somatic mutations or gene fusions in the following genes: EGFR, ALK, ROS1, NTRK, BRAF V600E and KRAS
  • Active malignancies other than for disease requiring therapy

Trial locations and contacts

179 sites in 15 countries.

179 sites in 15 countries

United States27 sites

  • Hawaii Cancer Care

    ‘Aiea, Hawaii, 96701

  • Emory University

    Atlanta, Georgia, 30022

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina, 28204

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee, 37404

  • Oncology Hematology Care

    Cincinnati, Ohio, 45242

  • Rocky Mountain Cancer Centers

    Colorado Springs, Colorado, 80907

  • Nationwide Children's Hospital

    Columbus, Ohio, 43205

  • Texas Oncology Baylor Charles A Sammons Cancer Center

    Dallas, Texas, 75246

  • Henry Ford Hospital

    Detroit, Michigan, 48202

  • Texas Oncology-Fort Worth Cancer Center

    Fort Worth, Texas, 76104

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601

  • Memorial Cancer Institute

    Hollywood, Florida, 33021

  • MD Anderson

    Houston, Texas, 77030

  • Oncology Consultants Texas

    Houston, Texas, 77030

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256

  • Tennessee Oncology

    Nashville, Tennessee, 37203

  • Mount Sinai

    New York, New York, 10029

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10128

  • Texas Oncology Odessa-West Texas Cancer Center

    Odessa, Texas, 79761

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232

  • Texas Oncology San Antonio Northeast

    San Antonio, Texas, 78217

  • Maine Medical Center

    Scarborough, Maine, 04074

  • NorthWest Medical Specialties, PLLC

    Tacoma, Washington, 98405

  • Arizona Oncology Associates, PC - HOPE

    Tucson, Arizona, 85711

  • Aurora Research Institute

    Wauwatosa, Wisconsin, 53226

Other trials in United States

China18 sites

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, 100021

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, 100070

  • Peking University Third Hospital

    Beijing, 100191

  • Chinese PLA General Hospital

    Beijing, 100853

  • Beijing Luhe Hospital, Capital Medical University

    Beijing, 101100

  • Jilin cancer hospital

    Changchun, 130012

  • The First Hospital of Jilin University

    Changchun, 130021

  • West China Hospital,Sichuan University

    Chengdu, 610041

  • Chongqing Southwest Hospital

    Chongqing, 400038

  • Third Military Medical University Daping Hospital Cancer Center

    Chongqing, 400042

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, 510289

  • First affiliated Hospital of Zhejiang University

    Hangzhou, 310003

  • Zhejiang Cancer Hospital

    Hangzhou, 310022

  • Eastern Theater General Hospital, Qinhuai District Medical Area

    Nanjing, 210002

  • Ruijin Hospital Shanghai Jiao Tong University

    Shanghai, 200025

  • Cancer Hospital, FuDan University

    Shanghai, 200032

  • Shanghai Zhongshan Hospital

    Shanghai, 200032

  • Huashan Hospital Fudan University

    Shanghai, 200040

Other trials in China

Brazil16 sites

  • Fundacao Pio XII

    Barretos, 14784-400

  • Liga Paranaense de Combate ao Cancer

    Curitiba, 81520 060

  • Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge

    Goiânia, 74605-070

  • Associacao Hospital de Caridade Ijui

    Ijuí, 98700-000

  • Liga Norte Riograndense Contra O Cancer

    Natal, 59075-740

  • Irmandade Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, 90050-170

  • Instituto de Medicina Integral Professor Fernando Figueira

    Recife, 50070-550

  • Oncoclinicas Rio de Janeiro S A

    Rio de Janeiro, 22250 905

  • Instituto D Or de Pesquisa e Ensino IDOR

    Rio de Janeiro, 22281 100

  • Hospital Sao Rafael

    Salvador, 41253 190

  • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo

    São Paulo, 01246 000

  • Sociedade Beneficente de Senhoras Hospital Sirio Libanes

    São Paulo, 01308 901

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, 01321-001

  • Fundacao Antonio Prudente A C Camargo Cancer Center

    São Paulo, 01509 900

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, 05410-030

  • GRAACC

    São Paulo, 4039001

Other trials in Brazil

Spain13 sites

  • Hosp. Univ. Quiron Dexeus

    Barcelona, 08028

  • Hosp Univ Vall D Hebron

    Barcelona, 08035

  • Hosp Clinic de Barcelona

    Barcelona, 08036

  • Hosp. Sant Joan de Deu

    Barcelona, 08950

  • Inst. Cat. Doncologia-H Duran I Reynals

    L'Hospitalet de Llobregat, 08908

  • Hosp. Infantil Univ. Nino Jesus

    Madrid, 28009

  • Clinica Univ. de Navarra

    Madrid, 28027

  • Hosp. Univ. Ramon Y Cajal

    Madrid, 28034

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040

  • Hosp. Univ. 12 de Octubre

    Madrid, 28041

  • Hosp. Univ. La Paz

    Madrid, 28046

  • Hosp. Virgen Del Rocio

    Seville, 41013

  • Hosp. Clinico Univ. de Valencia

    Valencia, 46010

Other trials in Spain

Argentina12 sites

  • Instituto de Investigaciones Metabólicas

    Buenos Aires, C1012AAR

  • Hospital Aleman

    Buenos Aires, C1118AAT

  • Centro Oncológico Korben

    Buenos Aires, C1426AGE

  • Instituto Fleni

    Buenos Aires, C1428AQK

  • CEMIC Saavedra

    Buenos Aires, C1431FWN

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, 5000

  • Hospital Italiano de La Plata

    La Plata Lpl Lpl, 1900

  • Instituto de Investigaciones Clinicas Mar del Plata

    Mar del Plata, B7600FZN

  • Hospital Privado de Comunidad

    Mar del Plata, B7602CBM

  • Hospital Universitario Austral

    Pilar, 1629

  • Sanatorio Britanico de Rosario

    Rosario, 2000

  • ARS Médica

    San Salvador de Jujuy, Y4600AFW

Other trials in Argentina

Germany12 sites

  • Charité

    Berlin, 10115

  • Universitaetsklinikum Koeln

    Cologne, 50937

  • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden

    Dresden, 01307

  • Universitaetsklinikum Essen

    Essen, 45147

  • Universitaetsklinikum Frankfurt

    Frankfurt, 60385

  • Asklepios Klinik Altona

    Hamburg, 22763

  • Universitaetsklinikum Heidelberg 1

    Heidelberg, 69120

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120

  • Universitaetsklinikum Leipzig

    Leipzig, 04103

  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz

    Mainz, 55131

  • Klinikum rechts der Isar der TU Munchen

    München, 81675

  • Universitatsklinikum Tubingen

    Tübingen, 72076

Other trials in Germany

South Korea12 sites

  • Severance Hospital Yonsei University Health System 1

    Seoul, 03722

  • Severance Hospital Yonsei University Health System 2

    Seoul, 03722

  • Severance Hospital Yonsei University Health System

    Seoul, 03722

  • Asan Medical Center 1

    Seoul, 05505

  • Asan Medical Center 2

    Seoul, 05505

  • Asan Medical Center

    Seoul, 05505

  • Samsung Medical Center 1

    Seoul, 06351

  • Samsung Medical Center 2

    Seoul, 06351

  • Samsung Medical Center

    Seoul, 06351

  • The Catholic University of Korea Seoul St Marys Hospital 1

    Seoul, 06591

  • The Catholic University of Korea Seoul St Marys Hospital

    Seoul, 06591

  • Seoul National University Hospital

    Seoul, 3080

Other trials in South Korea

Taiwan12 sites

  • Changhua Christian Hospital

    Changhua, 50006

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, 807

  • E-Da Cancer Hospital

    Kaohsiung City, 82445

  • Chang Gung Medical Foundation

    Kaohsiung City, 833

  • China Medical University Hospital

    Taichung, 403

  • Taichung Veterans General Hospital

    Taichung, 40705

  • Chi Mei Medical Center Yong Kang

    Tainan, 710

  • National Cheng Kung University Hospital

    Tainan, 710

  • Chi Mei Medical Center Liu Ying

    Tainan, 736

  • National Taiwan University Hospital

    Taipei, 10002

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Memorial Hospital Linkou Branch

    Taoyuan City, 333

Other trials in Taiwan

Belgium11 sites

  • AZ Klina

    Brasschaat, 2930

  • UCL Hopital Saint-Luc

    Brussels, 1200

  • Grand Hopital de Charleroi, site Notre Dame

    Charleroi, 6000

  • CHU UCL Namur - Site Dinant

    Dinant, 5500

  • UZA

    Edegem, 2650

  • AZ Maria Middelares

    Ghent, 9000

  • UZ Gent

    Ghent, 9000

  • Jolimont

    Haine-Saint-Paul, 7100

  • CHU UCL Namur - Site Sainte Elisabeth

    Namur, 5000

  • Cliniques St Pierre

    Ottignies, 1340

  • CHU UCL Namur - Site Godinne

    Yvoir, 5530

Other trials in Belgium

France11 sites

  • Hopital Saint André

    Bordeaux, 33075

  • Centre Francois Baclesse

    Caen, 14000

  • Centre Jean Perrin

    Clermont-Ferrand, 63011

  • Centre Georges Francois Leclerc

    Dijon, 21000

  • Centre Oscar Lambret

    Lille, 59000

  • Centre Leon Berard

    Lyon, 69008

  • Hopital de la Timone

    Marseille, 130005

  • Institut Curie

    Paris, 75005

  • CHU De Poitiers

    Poitiers, 86021

  • Institut de Cancerologie de Lorraine

    Vandœuvre-lès-Nancy, 54519

  • Institut Gustave Roussy

    Villejuif, 94800

Other trials in France

Italy9 sites

  • Istituto Ortopedico Rizzoli

    Bologna, 40136

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, 20162

  • ASST di Monza

    Monza, 20900

  • Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli

    Naples, 80138

  • Fondazione G Pascale Istituto Nazionale Tumori IRCCS

    Naples, 80138

  • Ospedale S. Maria Della Misericordia

    Perugia, 06132

  • Ospedale Santa Chiara AO Universitaria Pisana

    Pisa, 56126

  • Azienda Ospedaliera S. Maria Terni

    Terni, 5100

  • Ospedale Borgo Roma

    Verona, 37134

Other trials in Italy

Poland8 sites

  • Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy

    Bydgoszcz, 85 796

  • Przychodnia Lekarska KOMED Roman Karaszewski

    Konin, 62-500

  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie

    Krakow, 31 501

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi

    Lodz, 93 513

  • Centrum Medyczne Pratia Poznan

    Skorzewo, 60 185

  • Instytut Matki i Dziecka

    Warsaw, 01 211

  • Centralny Szpital Kliniczny MSWiA w Warszawie

    Warsaw, 02-507

  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy

    Warsaw, 02-781

Other trials in Poland

United Kingdom7 sites

  • Bristol Royal Hospital for Children

    Bristol, BS2 8AE

  • Bristol Haematology and Oncology Centre

    Bristol, BS2 8ED

  • The Christie Nhs Foundation Trust

    Manchester, M20 4BX

  • The Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, CH63 4JY

  • Freeman Hospital

    Newcastle upon Tyne, NE7 7DN

  • Derriford Hospital

    Plymouth, PL6 8DH

  • The Royal Marsden NHS Trust

    Sutton, SM2 5PT

Other trials in United Kingdom

Australia6 sites

  • Flinders Centre for Innovation in Cancer

    Adelaide, 5042

  • Chris O'Brien Lifehouse

    Camperdown, 2050

  • St Vincent s Hospital Sydney

    Darlinghurst, 2010

  • St Vincents Hospital Melbourne

    Fitzroy, 3065

  • Fiona Stanley Hospital

    Murdoch, 6150

  • Intergrated Clinical Oncology Network Pty Ltd (ICON)

    South Brisbane, 4101

Other trials in Australia

Japan5 sites

  • National Cancer Center Hospital

    Chūōku, 104 0045

  • Hiroshima University Hospital

    Hiroshima, 734 8551

  • National Cancer Center Hospital East

    Kashiwa, 277 8577

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, 791-0280

  • Fujita Health University Hospital

    Toyoake, 470-1192

Other trials in Japan

About this study

Official title: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations (mutations or gene fusions). It will also evaluate ORR in pediatric participants with advanced solid tumors and FGFR alterations.

Read the detailed description

Erdafitinib is a selective and potent pan FGFR 1-4 inhibitor with demonstrated clinical activity in participants with metastatic urothelial cancer and cholangiocarcinoma identified to have alterations in the FGFR pathway. This study targets the underlying altered biology of FGFR-driven tumors irrespective of solid tumor histology subtype. The study consists of screening phase, treatment phase and the post treatment follow-up phase (from the end of treatment visit until the participant has died, withdraws consent, is lost to follow-up, or the end of study, whichever comes first). End of study is considered as the time when the last participant receives the last dose of study drug on the study and either all pediatric participants are off study or until the most recently enrolled pediatric participant still participating in the study has 6 months of follow-up, whichever occurs first. Currently this study is recruiting pediatric participants only.

Being tested
Erdafitinib

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ErdafitinibDrug

    Also called JNJ-42756493

    Participants will receive erdafitinib oral tablets.

Study groups in NCT04083976
Study groupRoleWhat they receive
ErdafitinibExperimentalParticipants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, decision by the investigator to discontinue treatment, or end of data collection timepoint if there is clinical benefit in the opinion of the investigator, has been achieved.
Receives: Drug: Erdafitinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)

    ORR is defined as the percentage of participants who achieved a complete response (CR), or partial response (PR) based on Response Assessment in Neuro-Oncology (RANO) criteria. According to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions; PR: sum of products of diameters [SPD] decreased by >=50 percent [%] from baseline value) and clinical performance status with steroid dose information.

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years

  2. Core Panel Cohort: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)

    ORR is defined as the percentage of participants who achieved a CR, or PR based on RANO criteria. According to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions; PR: sum of products of diameters [SPD] decreased by >=50 percent [%] from baseline value) and clinical performance status with steroid dose information. The core panel cohort is a subgroup of the broad panel cohort with a select panel of pre-specified FGFR markers: FGFR3 mutations (S249C;Y373C; R248C; G370C); FGFR2 mutations (C382R); FGFR3 fusions (FGFR3-TACC3); FGFR2 fusions (FGFR2-BICC1; FGFR2-TACC2).

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 4 years

Secondary outcomes (14)

  1. Objective Response Rate (ORR) as Assessed by Investigator Assessment

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  2. Duration of Responses (DOR)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  3. Disease Control Rate (DCR)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  4. Clinical Benefit Rate (CBR)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  5. Progression-free Survival (PFS)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  6. Overall Survival (OS)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  7. Number of Participants With Adverse Events (AEs)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  8. Number of Participants With Adverse Events (AEs) by Severity

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  9. Plasma Concentration of Erdafitinib

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  10. Broad Panel, CCA Expansion, and Exploratory Cohorts: Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  11. Pediatric Cohorts: Change From Baseline in Pediatric Functional Assessment Of Cancer Therapy-Brain (Peds FACT-Br)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  12. Change From Baseline in Patient Global Impression of Symptom Severity (PGIS)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  13. Change From Baseline in Patient Global Impression of Change (PGIC)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

  14. Change From Baseline in European Quality of Life -5 Dimensions-5 Levels (EQ-5D-5L)

    Measured: Baseline (Cycle 1 Day 1 [each cycle of 21 days]) up to 5 years 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Sep 2019
  2. Study start20 Nov 2019
  3. Primary completion4 Dec 2023
  4. Study completion28 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
316 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04083976
Sponsor's protocol ID
CR108661
Other IDs
42756493CAN2002, 2019-002113-19, 2023-510301-18-00, 2023, 2019
Acronym
RAGNAR
Status last verified
Aug 2026
First submitted
6 Sep 2019
Last updated
17 Sep 2026
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Publications

  • Carranza O, Pant S, Schuler M, Witt O, Geoerger B, Loriot Y, Farouk Sait S, Arnold D, Dal Molin GZ, Lugowska I, Winter H, Baldini C, Corassa M, Thomas S, Crow L, Xia Y, Triantos S, Sweiti H, Reardon DA. Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts. JCO Precis Oncol. 2026 Jul;10(7):e2501094. doi: 10.1200/PO-25-01094. Epub 2026 Jul 15.

    PubMed 42456086

  • Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9.

    PubMed 37541273

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in